Medicine and Dentistry
Inflammatory Bowel Disease
96%
Crohn's Disease
91%
Ulcerative Colitis
63%
Cohort Analysis
47%
Patient with Inflammatory Bowel Disease
36%
Patient with Crohn's Disease
32%
Disease
31%
Quality of Life
29%
Disease Activity
29%
Fecal Microbiota Transplantation
28%
Biological Therapy
27%
Capsule Endoscopy
26%
Tumor Necrosis Factor
26%
Patient with Ulcerative Colitis
19%
Infliximab
19%
Psoriatic Arthritis
18%
Randomized Controlled Trial
17%
Placebo
17%
Diagnosis
16%
Infection
15%
Biological Marker
15%
TNF Inhibitor
15%
Diagnostic Accuracy
13%
Inflammatory Disorder
13%
Irritable Bowel Syndrome
12%
Hereditary Hemorrhagic Telangiectasia
12%
Hazard Ratio
12%
Disease Course
12%
Faecal Calprotectin
11%
Health Care Cost
11%
Drug Therapy
10%
Personalized Medicine
10%
Combination Therapy
10%
Mucosa
9%
Elderly Patient
9%
COVID-19
9%
C Reactive Protein
8%
Biological Product
8%
Colon
8%
Primary Health Care
7%
Computed Tomography Enterography
7%
Mesalazine
7%
Ileo-Anal Pouch
7%
Odds Ratio
7%
Immunomodulating Agent
7%
Maintenance Therapy
6%
Pouchitis
6%
Birth Outcomes
6%
Postoperative Complication
6%
Fistula
6%
Pharmacology, Toxicology and Pharmaceutical Science
Crohn's Disease
100%
Inflammatory Bowel Disease
97%
Ulcerative Colitis
71%
Cohort Study
49%
Disease Activity
37%
Infliximab
36%
Disease
32%
Tumor Necrosis Factor
24%
Psoriatic Arthritis
22%
Feces microflora
21%
Tumor Necrosis Factor Inhibitor
21%
Biological Marker
21%
Infection
21%
Placebo
17%
Inflammatory Disease
14%
Remission
13%
Biological Product
11%
Aminosalicylic Acid
11%
Irritable Colon
10%
Adalimumab
10%
Immunomodulating Agent
9%
Rendu Osler Weber Disease
9%
Calgranulin
8%
Inflammation
7%
Dicarbonate
7%
Randomized Controlled Trial
7%
Inflammatory Arthritis
7%
Wound Healing
7%
Combination Therapy
7%
Prothrombin
6%
Mercaptopurine
6%
Rheumatoid Arthritis
6%
Vedolizumab
6%
Leukotriene B4
6%
Congenital Blood Vessel Malformation
6%
Prednisolone
6%
Anticoagulant Agent
6%
Colitis
5%
Dextran Sulfate
5%
Prevalence
5%
Premature Labor
5%
Disease Course
5%
Bevacizumab
5%
C Reactive Protein
5%
Immunology and Microbiology
Crohn's Disease
70%
Ulcerative Colitis
59%
Inflammatory Bowel Disease
58%
Infliximab
28%
Inflammatory Disorder
23%
Psoriatic Arthritis
14%
Extracellular Matrix
12%
Feces microflora
12%
Colitis
11%
Basement Membrane
11%
Tumor Necrosis Factor
11%
Wound Healing
10%
Biological Product
10%
Inflammatory Arthritis
8%
Normal Human
8%
Prednisolone
7%
Laminin
6%
Drug Dose Intensification
6%
T Cell
6%
Adolescence
6%
TNF Inhibitor
6%
Adalimumab
5%
Immunity
5%
